• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reveromycin A, a novel acid-seeking agent, ameliorates bone destruction and tumor growth in multiple myeloma.

作者信息

Watanabe Keiichiro, Bat-Erdene Ariunzaya, Tenshin Hirofumi, Cui Qu, Teramachi Jumpei, Hiasa Masahiro, Oda Asuka, Harada Takeshi, Miki Hirokazu, Sogabe Kimiko, Oura Masahiro, Sumitani Ryohei, Mitsui Yukari, Endo Itsuro, Tanaka Eiji, Kawatani Makoto, Osada Hiroyuki, Matsumoto Toshio, Abe Masahiro

机构信息

Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.

School of Bio-Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia.

出版信息

Haematologica. 2021 Apr 1;106(4):1172-1177. doi: 10.3324/haematol.2019.244418.

DOI:10.3324/haematol.2019.244418
PMID:32586903
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8018113/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/227b/8018113/0d022565c8e4/1061172.fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/227b/8018113/1ad694f905f6/1061172.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/227b/8018113/321ea0395f8c/1061172.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/227b/8018113/0d022565c8e4/1061172.fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/227b/8018113/1ad694f905f6/1061172.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/227b/8018113/321ea0395f8c/1061172.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/227b/8018113/0d022565c8e4/1061172.fig3.jpg

相似文献

1
Reveromycin A, a novel acid-seeking agent, ameliorates bone destruction and tumor growth in multiple myeloma.瑞维霉素A，一种新型的趋酸剂，可改善多发性骨髓瘤中的骨质破坏和肿瘤生长。
Haematologica. 2021 Apr 1;106(4):1172-1177. doi: 10.3324/haematol.2019.244418.
2
Reveromycin A inhibits osteolytic bone metastasis of small-cell lung cancer cells, SBC-5, through an antiosteoclastic activity.瑞弗霉素A通过抗破骨细胞活性抑制小细胞肺癌细胞SBC-5的溶骨性骨转移。
Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8822-8. doi: 10.1158/1078-0432.CCR-05-1335.
3
Synthesis and biological activities of reveromycin A and spirofungin A derivatives.瑞弗霉素A和螺旋真菌素A衍生物的合成及生物活性
Bioorg Med Chem Lett. 2008 Jul 1;18(13):3756-60. doi: 10.1016/j.bmcl.2008.05.054. Epub 2008 May 17.
4
Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts.瑞伐霉素A是一种治疗骨质疏松症的药物，通过特异性诱导破骨细胞凋亡来抑制骨吸收。
Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4729-34. doi: 10.1073/pnas.0505663103. Epub 2006 Mar 13.
5
Pathophysiology of multiple myeloma bone disease.多发性骨髓瘤骨病的病理生理学
Hematol Oncol Clin North Am. 2007 Dec;21(6):1035-49, viii. doi: 10.1016/j.hoc.2007.08.009.
6
Chemical and biological studies of reveromycin A.瑞弗霉素A的化学与生物学研究
J Antibiot (Tokyo). 2016 Oct;69(10):723-730. doi: 10.1038/ja.2016.57. Epub 2016 Jun 8.
7
[Bone hyperresorption in multiple myeloma].[多发性骨髓瘤中的骨高吸收]
Presse Med. 2000 Mar 11;29(9):492-7.
8
Reveromycin A-Induced Apoptosis in Osteoclasts Is Not Accompanied by Necrosis.
J Cell Biochem. 2015 Aug;116(8):1646-57. doi: 10.1002/jcb.25125.
9
Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts.外泌体通过靶向作用于破骨细胞和成骨细胞在多发性骨髓瘤骨病和肿瘤发展中发挥作用。
Blood Cancer J. 2018 Nov 8;8(11):105. doi: 10.1038/s41408-018-0139-7.
10
Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease.巨噬细胞炎性蛋白-1α在小鼠骨髓瘤骨病5TGM1模型中对骨溶解和肿瘤负荷的双重作用。
Blood. 2003 Jul 1;102(1):311-9. doi: 10.1182/blood-2002-12-3905. Epub 2003 Mar 20.

引用本文的文献

1
Biosynthesis of reveromycin derivatives by altering the regioselectivity of cytochrome P450revI.通过改变细胞色素P450revI的区域选择性来生物合成瑞弗霉素衍生物。
Chem Sci. 2025 Jun 23. doi: 10.1039/d5sc01355k.
2
Chemical biology research in RIKEN NPDepo aimed at agricultural applications.理化学研究所天然产物宝库（RIKEN NPDepo）针对农业应用开展化学生物学研究。
Proc Jpn Acad Ser B Phys Biol Sci. 2025;101(1):8-31. doi: 10.2183/pjab.101.003.
3
Inhibition of PI3K Class IA Kinases Using GDC-0941 Overcomes Cytoprotection of Multiple Myeloma Cells in the Osteoclastic Bone Marrow Microenvironment Enhancing the Efficacy of Current Clinical Therapeutics.

本文引用的文献

1
Acidosis and proteolysis in the tumor microenvironment.肿瘤微环境中的酸中毒和蛋白水解作用。
Cancer Metastasis Rev. 2019 Jun;38(1-2):103-112. doi: 10.1007/s10555-019-09796-3.
2
Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors.帕比司他和蛋白酶体抑制剂对Sp1（骨髓瘤细胞生长和存活的关键转录因子）的协同靶向作用。
Oncotarget. 2016 Nov 29;7(48):79064-79075. doi: 10.18632/oncotarget.12594.
3
A vicious cycle between acid sensing and survival signaling in myeloma cells: acid-induced epigenetic alteration.
使用GDC-0941抑制I类PI3K激酶可克服破骨细胞性骨髓微环境中多发性骨髓瘤细胞的细胞保护作用，增强当前临床治疗方法的疗效。
Cancers (Basel). 2023 Jan 11;15(2):462. doi: 10.3390/cancers15020462.
4
Myeloma-Bone Interaction: A Vicious Cycle via TAK1-PIM2 Signaling.骨髓瘤与骨的相互作用：通过TAK1-PIM2信号传导形成的恶性循环。
Cancers (Basel). 2021 Sep 3;13(17):4441. doi: 10.3390/cancers13174441.
骨髓瘤细胞中酸感应与生存信号之间的恶性循环：酸诱导的表观遗传改变
Oncotarget. 2016 Oct 25;7(43):70447-70461. doi: 10.18632/oncotarget.11927.
4
Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche.破骨细胞通过重塑骨内膜微环境来控制休眠骨髓瘤细胞的重新激活。
Nat Commun. 2015 Dec 3;6:8983. doi: 10.1038/ncomms9983.
5
Up-regulation of hexokinaseII in myeloma cells: targeting myeloma cells with 3-bromopyruvate.上调骨髓瘤细胞中的己糖激酶 II：用 3-溴丙酮酸靶向骨髓瘤细胞。
J Bioenerg Biomembr. 2012 Feb;44(1):31-8. doi: 10.1007/s10863-012-9412-9.
6
Significant biological role of sp1 transactivation in multiple myeloma.sp1 转录激活在多发性骨髓瘤中的重要生物学作用。
Clin Cancer Res. 2011 Oct 15;17(20):6500-9. doi: 10.1158/1078-0432.CCR-11-1036. Epub 2011 Aug 19.
7
The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells.丝氨酸/苏氨酸激酶 Pim-2 是骨髓瘤细胞中一种新型的抗凋亡介质。
Leukemia. 2011 Jul;25(7):1182-8. doi: 10.1038/leu.2011.60. Epub 2011 Apr 8.
8
Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth.TGF-β 抑制可恢复终末成骨细胞分化，从而抑制骨髓瘤生长。
PLoS One. 2010 Mar 25;5(3):e9870. doi: 10.1371/journal.pone.0009870.
9
Osteoclast-targeting small molecules for the treatment of neoplastic bone metastases.用于治疗肿瘤性骨转移的靶向破骨细胞小分子药物。
Cancer Sci. 2009 Nov;100(11):1999-2005. doi: 10.1111/j.1349-7006.2009.01294.x. Epub 2009 Jul 21.
10
Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics.肿瘤pH值控制弱酸和弱碱化疗药物的体内疗效。
Mol Cancer Ther. 2006 May;5(5):1275-9. doi: 10.1158/1535-7163.MCT-06-0024.